Education
About Us
Working with TipRanks
Follow Us
MedCap AB (DE:61MA)
FRANKFURT:61MA
61MA Stock Chart & Stats
€50.30
€0.90(1.70%)
At close: 4:00 PM EST
€50.30
€0.90(1.70%)
Day’s Range― - ―
52-Week Range€29.40 - €59.60
Previous CloseN/A
Volume0.00
Average Volume (3M)4.00
Market Cap
€670.41M
Enterprise Value€7.59B
Total Cash (Recent Filing)€370.40M
Total Debt (Recent Filing)€707.00M
Price to Earnings (P/E)33.2
Beta0.11
Next Earnings
Apr 29, 2026EPS Estimate
0.44Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding15,077,583
10 Day Avg. Volume0
30 Day Avg. Volume4
Financial Highlights & Ratios
PEG Ratio7.70
Price to Book (P/B)5.67
Price to Sales (P/S)3.90
P/FCF Ratio29.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Scale & ProfitabilitySustained multi‑year revenue growth to ~2.1B and consistently mid‑teens EBIT margins create a durable earnings base. Scale across operating subsidiaries supports pricing power, operating leverage and reinvestment capacity, underpinning long‑term profit stability and growth execution.
Consistent Free Cash FlowPositive and growing free cash flow over multiple years indicates the group converts earnings into real cash, enabling dividend upstreaming, organic investment and bolt‑on M&A without immediate dependence on equity issuance. That cash resiliency supports durable financial flexibility.
Niche M&A Model & Capital EfficiencyA focused buy‑and‑build approach in medical tech and diagnostics leverages sector expertise to create value. Coupled with mid‑teens ROE noted in the balance sheet, this model promotes predictable capital deployment, operational improvements and scaled cash generation across holdings.
Bears Say
Rising LeverageA meaningful step‑up in debt and higher debt‑to‑equity reduces balance‑sheet flexibility, raising refinancing and covenant risk. Increased leverage can constrain future acquisitions or upstreaming of cash and amplifies earnings volatility impact if margins or cash flow weaken.
Uneven Cash ConversionInconsistent conversion of reported earnings to operating cash implies working‑capital swings or timing effects. That unpredictability weakens liquidity reliability, complicates planning for capex/dividends and can necessitate short‑term funding that increases financing costs or leverage.
Gross Margin VolatilityA notable decline in gross margin signals exposure to cost inflation, mix shifts or one‑offs that directly compress operating profit. Persistent margin volatility would erode the company's ability to sustainably fund growth initiatives and heighten sensitivity to external price pressures.
MedCap AB News
61MA FAQ
What was MedCap AB’s price range in the past 12 months?
MedCap AB lowest stock price was €29.40 and its highest was €59.60 in the past 12 months.
What is MedCap AB’s market cap?
MedCap AB’s market cap is €670.41M.
When is MedCap AB’s upcoming earnings report date?
MedCap AB’s upcoming earnings report date is Apr 29, 2026 which is in 65 days.
How were MedCap AB’s earnings last quarter?
MedCap AB released its earnings results on Feb 06, 2026. The company reported €0.453 earnings per share for the quarter, beating the consensus estimate of €0.446 by €0.007.
Is MedCap AB overvalued?
According to Wall Street analysts MedCap AB’s price is currently Overvalued.
Does MedCap AB pay dividends?
MedCap AB does not currently pay dividends.
What is MedCap AB’s EPS estimate?
MedCap AB’s EPS estimate is 0.44.
How many shares outstanding does MedCap AB have?
MedCap AB has 15,077,583 shares outstanding.
What happened to MedCap AB’s price movement after its last earnings report?
MedCap AB reported an EPS of €0.453 in its last earnings report, beating expectations of €0.446. Following the earnings report the stock price went up 8.994%.
Which hedge fund is a major shareholder of MedCap AB?
Currently, no hedge funds are holding shares in DE:61MA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
MedCap AB
MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, and pharmaceuticals companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Northern Europe. It typically invests between SEK25 million ($2.75 million) to SEK150 million ($16.51 million) with enterprise value and sales revenue between SEK50 million ($5.90 million) to SEK200 million ($23.06 million) and EBITDA between SEK1 million ($0.11 million) to SEK50 million ($5.50 million). The firm seeks to acquire stakes between 20% and 50% in its portfolio companies. It uses its capital and loans and makes balance sheet investments. MedCap AB (publ) was founded in 2001 and is based in Stockholm, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---